Phosphatidylinositol 3 kinase contributes to the transformation of hematopoietic cells by the D816V c-Kit mutant
about
Functional deregulation of KIT: link to mast cell proliferative diseases and other neoplasmsControl of Oocyte Reawakening by Kit.Germline mutations of KIT in gastrointestinal stromal tumor (GIST) and mastocytosisGab2 is involved in differential phosphoinositide 3-kinase signaling by two splice forms of c-KitAML1 interconnected pathways of leukemogenesisThe Kasumi-1 cell line: a t(8;21)-kit mutant model for acute myeloid leukemiaMutation D816V alters the internal structure and dynamics of c-KIT receptor cytoplasmic region: implications for dimerization and activation mechanismsPrevalence and prognostic significance of KIT mutations in pediatric patients with core binding factor AML enrolled on serial pediatric cooperative trials for de novo AML.Expression of c-kit receptor in human cholangiocarcinoma and in vivo treatment with imatinib mesilate in chimeric miceNeoplasms associated with germline and somatic NF1 gene mutationsThe synergy between stem cell factor (SCF) and granulocyte colony-stimulating factor (G-CSF): molecular basis and clinical relevance.Unique effects of KIT D816V in BaF3 cells: induction of cluster formation, histamine synthesis, and early mast cell differentiation antigens.Tyrosine Kinase Inhibitors and Therapeutic Antibodies in Advanced Eosinophilic Disorders and Systemic Mastocytosis.Oncogenic Kit signals on endolysosomes and endoplasmic reticulum are essential for neoplastic mast cell proliferation.Enforced differentiation of Dnmt3a-null bone marrow leads to failure with c-Kit mutations driving leukemic transformationGiant gastrointestinal stromal tumor presenting as a palpable abdominal mass: an unusual presentation.Rho kinase regulates the survival and transformation of cells bearing oncogenic forms of KIT, FLT3, and BCR-ABL.PTEN deficiency in mast cells causes a mastocytosis-like proliferative disease that heightens allergic responses and vascular permeabilityBiology of gastrointestinal stromal tumors: KIT mutations and beyond.On the way to targeted therapy of mast cell neoplasms: identification of molecular targets in neoplastic mast cells and evaluation of arising treatment concepts.Lipid rafts are required for Kit survival and proliferation signalsMastocytosis: a mutated KIT receptor induced myeloproliferative disorderRoles for deregulated receptor tyrosine kinases and their downstream signaling molecules in hematologic malignancies.Oncogenic KIT mutations in different exons lead to specific changes in melanocyte phospho-proteome.Is cancer a disease of abnormal cellular metabolism? New angles on an old ideaThe phosphoinositide 3-kinase pathway in human cancer: genetic alterations and therapeutic implications.Expression of activated STAT5 in neoplastic mast cells in systemic mastocytosis: subcellular distribution and role of the transforming oncoprotein KIT D816V.Therapeutic targeting of c-KIT in cancer.Engineering CHO cells with an oncogenic KIT improves cells growth, resilience to stress and productivity.The activation loop tyrosine 823 is essential for the transforming capacity of the c-Kit oncogenic mutant D816V.The PI3-kinase isoform p110δ is essential for cell transformation induced by the D816V mutant of c-Kit in a lipid-kinase-independent manner.The D816V mutation of c-Kit circumvents a requirement for Src family kinases in c-Kit signal transduction.Synergistic growth of stem cell factor and granulocyte macrophage colony-stimulating factor involves kinase-dependent and -independent contributions from c-Kit.Roles of stem cell factor/c-Kit and effects of Glivec/STI571 in human uveal melanoma cell tumorigenesis.Inhibition of phosphatidylinositol 3-kinase dephosphorylates BAD and promotes apoptosis in myeloid leukemias.Functional and phenotypic studies of two variants of a human mast cell line with a distinct set of mutations in the c-kit proto-oncogene.Genetic reduction of class IA PI-3 kinase activity alters fetal hematopoiesis and competitive repopulating ability of hematopoietic stem cells in vivo.Oncogenic KIT-induced aggressive systemic mastocytosis requires SHP2/PTPN11 phosphatase for disease progression in mice.Identification of oncostatin M as a STAT5-dependent mediator of bone marrow remodeling in KIT D816V-positive systemic mastocytosisGenetic and pharmacologic evidence implicating the p85 alpha, but not p85 beta, regulatory subunit of PI3K and Rac2 GTPase in regulating oncogenic KIT-induced transformation in acute myeloid leukemia and systemic mastocytosis.
P2860
Q26995624-BDB1D9DB-92D2-4E2D-8F9D-CD44849394E6Q27308132-2EBB35CD-A1EC-4FCC-ACF8-FD4167884240Q28080034-9BC03B4F-24BD-4686-83FE-58BBAD5C7DD5Q28115545-E16A0C84-E8EF-4853-9162-7F51B51AB0FCQ28184349-35A74AB6-1A81-4E7F-995D-C91029D49D07Q28300267-9049C77D-7C5F-45EF-91B5-CC5707A9AFC7Q28478611-21E592D1-DACB-4B8B-A52C-104CF8058D64Q33754603-98B2EDD2-4C2B-4EB1-84E9-D1644CA2120FQ34012590-707AB640-2018-4D5D-9324-335D40B9E639Q34125947-E390B3CF-4FDC-4D6D-AA09-53C04025B52DQ34142278-F06073DC-3A01-49D9-84D6-0CAD1298BC22Q34293285-E02133F5-5FE7-4028-8894-752AAD626479Q34495630-1681EDEB-DF66-4B96-B76E-9EC2C47DBDC2Q34833416-A4A213CC-FA7B-4EF1-96AB-950319537D42Q35004935-04C70F0F-0ED0-4EB8-BEEB-1FBE13AEF676Q35440087-1BB81D2E-7EF8-43EB-87DF-4DA98F789037Q35513750-98727C27-D663-483F-B008-A39C70935798Q35553313-FF3E9AD7-5948-4A33-A313-D5AAC5CD922FQ35740268-3FA2EF2A-00CA-424E-8DD0-726EE8867390Q35854970-4E729FD7-A4C3-4951-BDBC-F2087B7CFEB5Q35990629-6C9FB63D-F158-4BF9-A8A0-8688DBB12FFFQ36210845-9566F785-1712-4B52-B95D-0C1CCAEF0493Q37051428-BEDE17EA-4C8E-4F89-BE74-129E2924C7D4Q37262426-37CE5903-323D-41B8-BEB8-31D8DC3A5858Q37305385-89F1E75D-2A6F-4926-917D-6F88BB428741Q37454384-C7CB84CE-0441-4606-BBFA-2F2C9AA8F42CQ37462729-E425D8BF-03B5-4B4F-9B90-2877486FE55BQ38057806-964A93F1-5D03-4749-9033-A649E626CC47Q38719507-067BF9C0-993A-4D67-96F6-168CF7ABACD0Q38936739-CCEE7C10-E75B-42CC-B893-0C79A249C7A5Q39064868-A12B3D72-16FE-430E-84D2-A8626F80AD5AQ39876378-74046F8A-DF62-41D5-A0D0-5193026C4EE6Q40525943-FE4FEE0B-2189-4AF8-A184-D6C9074B8AA7Q40555586-DAEEDE49-119B-4728-95E3-C54991E41A36Q40615155-4C578255-4A9F-40E5-9CE5-6FF670586A60Q40678754-6966EB0C-356B-473A-8313-19667E454642Q41834449-D6B51CC7-F130-4211-AB58-638F1EFB8947Q41939033-6BE971FF-88DB-4351-85E0-D9B4CF05B19CQ42045097-EFA4A5AE-1CF6-4024-BDEF-C10699D47AB9Q42193246-CECD5ABB-D21A-4E59-A47B-1ECBFAB7D67A
P2860
Phosphatidylinositol 3 kinase contributes to the transformation of hematopoietic cells by the D816V c-Kit mutant
description
2001 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
artículu científicu espublizáu en 2001
@ast
im September 2001 veröffentlichter wissenschaftlicher Artikel
@de
scientific journal article
@en
vedecký článok (publikovaný 2001/09/01)
@sk
vědecký článek publikovaný v roce 2001
@cs
wetenschappelijk artikel (gepubliceerd op 2001/09/01)
@nl
наукова стаття, опублікована у вересні 2001
@uk
مقالة علمية (نشرت في سبتمبر 2001)
@ar
name
Phosphatidylinositol 3 kinase ...... ells by the D816V c-Kit mutant
@ast
Phosphatidylinositol 3 kinase ...... ells by the D816V c-Kit mutant
@en
Phosphatidylinositol 3 kinase ...... ells by the D816V c-Kit mutant
@nl
type
label
Phosphatidylinositol 3 kinase ...... ells by the D816V c-Kit mutant
@ast
Phosphatidylinositol 3 kinase ...... ells by the D816V c-Kit mutant
@en
Phosphatidylinositol 3 kinase ...... ells by the D816V c-Kit mutant
@nl
prefLabel
Phosphatidylinositol 3 kinase ...... ells by the D816V c-Kit mutant
@ast
Phosphatidylinositol 3 kinase ...... ells by the D816V c-Kit mutant
@en
Phosphatidylinositol 3 kinase ...... ells by the D816V c-Kit mutant
@nl
P2093
P3181
P356
P1433
P1476
Phosphatidylinositol 3 kinase ...... ells by the D816V c-Kit mutant
@en
P2093
A Danilkovitch-Miagkova
D Linnekin
P304
P3181
P356
10.1182/BLOOD.V98.5.1365
P407
P577
2001-09-01T00:00:00Z